6- (4- methyl- 1- (pyrimidin- 2- ylmethyl)pyrrolidin- 3- yl)- 1- (tetrahydro- 2H- pyran- 4- yl)- 1,5- dihydro- 4H- pyrazolo(3,4- d)pyrimidin- 4- one

a phosphodiesterase 9 inhibitor with cognitive enhancing activity; a nootropic agent

Also Known As:

6-((3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo(3,4-d)pyrimidin-4-one; PF-04447943

Networked: 5 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrazoles: 61
      - 6-(4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo(3,4-d)pyrimidin-4-one: 5
  - Pyrimidines: 510
    - Pyrimidinones: 71
      - 6-(4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo(3,4-d)pyrimidin-4-one: 5

Experts

1.	Dhar, Rana: 1 article (01/2021)
2.	Hu, Zhengqiang: 1 article (01/2021)
3.	Li, Yajun: 1 article (01/2021)
4.	Liu, Yuting: 1 article (01/2021)
5.	Lu, Jie: 1 article (01/2021)
6.	Ma, Wangqian: 1 article (01/2021)
7.	Rana, Mohammad Nasiruddin: 1 article (01/2021)
8.	Ruan, Jingjing: 1 article (01/2021)
9.	Tang, Huifang: 1 article (01/2021)
10.	Xue, Enfu: 1 article (01/2021)

Related Diseases

1.	Sickle Cell Anemia (Hemoglobin S Disease) 01/01/2019 - "PF-04447943, a Phosphodiesterase 9A Inhibitor, in Stable Sickle Cell Disease Patients: A Phase Ib Randomized, Placebo-Controlled Study." 01/01/2019 - "This phase Ib study randomized patients with stable sickle cell disease (SCD) aged 18-65 years to twice-daily PF-04447943 (a phosphodiesterase 9A inhibitor; 5 or 25 mg) or placebo, with/without hydroxyurea coadministration, for up to 29 days. "
2.	Alzheimer Disease (Alzheimer's Disease) 01/01/2014 - "A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer's disease." 01/01/2014 - "This Phase 2 multicenter study was designed to assess the efficacy, safety and pharmacokinetics of PF-04447943 compared with placebo in mild to moderate probable Alzheimer's disease (AD). "
3.	Cognitive Dysfunction 09/01/2011 - "Results with PF-04447943 are consistent with previously published findings using a structurally diverse PDE9 inhibitor, BAY73-6199, and further support the suggestion that PDE9 inhibition may represent a novel approach to the palliative remediation of cognitive dysfunction."
4.	Neurobehavioral Manifestations 01/01/2020 - "As PDE9A is a cGMP specific enzyme, drugs such as PF-04447943 which act to facilitate striatal cGMP signaling and glutamatergic corticostriatal transmission could be useful therapeutic agents for restoring striatal function and alleviating motor and cognitive symptoms associated with HD."
5.	Tetanus 09/01/2011 - "PF-04447943 significantly facilitated hippocampal slice LTP evoked by a weak tetanic stimulus at a concentration of 100 nM but failed to affect response to the weak tetanus at either 30 or 300 nM, or the LTP produced by a theta burst stimulus. "

Related Drugs and Biologics

1.	Phosphoric Diester Hydrolases (Phosphodiesterases)
2.	Hydroxyurea (Hydrea)
3.	Enzymes